Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market

Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market

Hologic (HOLX) could produce exceptional returns because of its solid growth attributes.

Is Hologic (HOLX) a Solid Growth Stock? 3 Reasons to Think " Yes "

Artisan Partners Asset Management

Camping World Hlds

M.D.C. Holdings

Top Ranked Growth Stocks to Buy for February 11th

ArcBest

Celestica

KB Home

Top Ranked Growth Stocks to Buy for February 9th

II-VI Incorporated

MaxLinear

Skyworks Solutions

Skyworks (SWKS), Hologic (HOLX), II-VI (IIVI) and MaxLinear (MXL) are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.

Invest in Stocks With Momentum Anomaly for Higher Returns

Fulgent Genetics

Scientists are beginning to arrive at the notion that the fight with Covid-19 is not a short raging battle that will be over by summer 2021 but a long-term war that will be waged for many years to come, with a constant need for PPE, testing, vaccine rejiggering, specialized air filtration solutions, and other ‘coping' […]

Stocks for the Pandemic Long Haul (NASDAQ: FLGT) (OTC US: ALST) (NASDAQ: HOLX)

Does Hologic (HOLX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Hologic (HOLX) is a Great Choice

Apple

Ford Motor Company

FedEx

Weyerhaeuser

At this stage, it will be prudent to invest in growth stocks with a favorable Zacks Rank. These are: AAPl, F, FDX, HOLX, WY.

5 Top-Ranked Growth Stocks to Tap Market Rally in February

Crocs

DCP Midstream

TEGNA

DCP Midstream (DCP), TEGNA (TGNA), Hologic (HOLX), Crocs (CROX) and Skyworks Solutions (SWKS) are five stocks with explosive relative price strength.

5 Relative Price Strength Stocks That Investors Will Love

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ESG--Hologic's New Sustainability Report Highlights How the Company's Purpose-Driven Culture is Making a Unique Difference in the World

Hologic's New Sustainability Report Highlights How the Company's Purpose-Driven Culture is Making a Unique Difference in the World

"We've clearly gotten a big bump up from our Covid testing," Hologic CEO Steve Macmillan said in a "Mad Money" interview.

Diagnostics provider Hologic expects Covid-19 testing capacities to boost business post-pandemic

Anavex Life Sciences

Axsome Therapeutics

Moderna

Novavax

Cassava Sciences Inc

Meridian Bioscience

Vaxart

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Biotech Bonanza: COVID Launches Science at Warp Speed

Lumber Liquidators

MACOM Technology Solutions Holdings

Vale S.A.

Top Ranked Growth Stocks to Buy for February 3rd

MarineMax

Solid Companies for Investors Interested in Medical Stocks and Big Boats.

Top Stock Picks for Week of February 1, 2021

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AI--Hologic and Google Cloud Announce Collaboration to Advance Next Generation Digital Diagnostic Capabilities

Hologic and Google Cloud Announce Collaboration to Advance Next Generation Digital Diagnostic Capabilities

Top Ranked Growth Stocks to Buy for February 1st

Is (HOLX) Outperforming Other Medical Stocks This Year?

Has Hologic (HOLX) Outpaced Other Medical Stocks This Year?

Hologic (HOLX) exhibited robust segmental growth in first-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Rise

Lennar

Mosaic

At this stage, it will be prudent to invest in large-cap stocks that have strong growth potential for 2021. These are: FDX, F, HOLX, MOS and LEN.

Wall Street Selloff Makes Good Entry Point: 5 Stocks to Grab

Hologic, Inc. (HOLX) CEO Steve MacMillan on Q1 2021 Results - Earnings Call Transcript

Hologic (HOLX) delivered earnings and revenue surprises of 33.64% and 0.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q1 Earnings Surpass Estimates

Shares of Hologic (NASDAQ:HOLX) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 368.85% year over year to $2.86, which beat the estimate of $2.17.

Recap: Hologic Q1 Earnings

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic Announces Financial Results for First Quarter of Fiscal 2021

Hologic Announces Financial Results for First Quarter of Fiscal 2021

America Movil SAB de CV

Hibbett Sports

PerkinElmer

Top Ranked Growth Stocks to Buy for January 27th

Hologic (HOLX) aims to optimize, simplify and streamline hysteroscopic workflow with the latest European launch of its fluid management system.

News for Hologic Stock (HOLX)